Palvella Therapeutics Announces Completion Of Rolling NDA Submission To FDA For QTORIN Rapamycin In Microcystic Lymphatic Malformations Under 505(b)(2) Pathway; FDA Filing Decision Expected Within 60 Days

뉴스 본문을 불러오고 있어요.

Palvella Therapeutics Announces Completion Of Rolling NDA Submission To FDA For QTORIN Rapamycin In Microcystic Lymphatic Malformations Under 505(b)(2) Pathway; FDA Filing Decision Expected Within 60 Days | 웨이프 WAPE

Palvella Therapeutics Announces Completion Of Rolling NDA Submission To FDA For QTORIN Rapamycin In Microcystic Lymphatic Malformations Under 505(b)(2) Pathway; FDA Filing Decision Expected Within 60 Days

기사 요약

관련 종목

댓글 —